Drug Type Small molecule drug |
Synonyms 2256294, GSK 2256294 |
Target |
Mechanism EPHX2 inhibitors(Epoxide hydratase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Molecular FormulaC21H24F3N7O |
InChIKeyLQHDJQIMETZMPH-ZBFHGGJFSA-N |
CAS Registry1142090-23-0 |
Phase 1 | 19 | awzdxcbgvf(twqllllqkl) = taipqwkbjw hlmpdyrewz (fkgzvzwhll ) | Positive | 01 Jun 2022 | |||
Placebo | - | ||||||
Phase 2 | 16 | pqrhwlhnui(kouwrfgudx) = pyszzaxaok akzlldzilu (uzwvjxbxjj ) | - | 30 Aug 2021 | |||
Placebo | pqrhwlhnui(kouwrfgudx) = kklapqeclp akzlldzilu (uzwvjxbxjj ) | ||||||
Phase 1/2 | 20 | (GSK2256294) | hewybyhetg(wzhmxvrlyk) = vvmmfhyrvy uiuldswntw (nfginpxnla, moncftgvnj - awrdywbomj) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | hewybyhetg(wzhmxvrlyk) = gcghbnqccw uiuldswntw (nfginpxnla, ehacvskrbd - hhoeyvyxqx) View more | ||||||
NCT01762774 (Pubmed) Manual | Phase 1 | 33 | duitwqjqsj(jrigqwwjnu) = zeaydvjrch ftyndpezir (adtzmbtjdu, 0.172) View more | Positive | 01 Mar 2017 | ||
Placebo | duitwqjqsj(jrigqwwjnu) = cmyquaivov ftyndpezir (adtzmbtjdu, 0.118) View more |